Infliximab is a chimeric (part human, part murine) therapeutic Monoclonal Antibody that targets tumour necrosis factor alpha (TNFα).

In Inflammatory Bowel Disease (IBD) and other immunological disorders such as Rheumatoid Arthritis (RA), the use of MAb therapy requires a personalised approach. The long term effectiveness of anti-TNFα agents such as Infliximab, is strongly influenced by its bioavailability, pharmacokinetics and immunogenicity.

Clinical trials have shown that over time a high proportion of patients lose response to treatment. In recognition of this phenomenon and in an attempt to better understand the course of disease there has been an increase in the use of therapeutic drug monitoring. Measuring serum trough drug levels to ensure an adequate drug concentration is maintained within a defined 'therapeutic window' is important for achieving clinical remission.

Failure to respond to biological treatments during the induction phase, or losing response during the maintenance phase, can be attributed to immunogenicity. Anti-TNFα Blockers (e.g. Infliximab and biosimilars (e.g. Remsima®, Inflectra®, Flixabi®)) may trigger immunogenic responses in individuals which can reduce the serum concentration of available drug thus altering its effectiveness.

Anti-Drug-Antibodies (ADA), impede drug activity and may cause severe allergic reactions too and so Infliximab is often administered with a concomitant immunosuppressant to reduce antibody formation, but it is not always indicated. Recent evidence suggests that once a patient is treated with concomitant immunosuppressants they must remain on them for the duration of the MAb treatment.

Anti-drug antibodies can also be measured in serum to help provide a more complete clinical picture as to why a patient may have lost control of their disease. A combination of therapeutic drug and anti-drug antibody monitoring provides a potential to preempt the course of disease, predict disease outcome, and to personalise a treatment strategy.

In IBD management, studies have shown that therapeutic drug monitoring strategies for infliximab and adalimumab are cost effective and significantly change the clinical decision-making when managing the disease.

IDKmonitor Infliximab Free Anti-drug antibody ELISA 96 wells

Product Code

K9650

Clinical Background

Index

© 2018 BIOHIT HealthCare Ltd

Contact Us

BIOHIT HealthCare Ltd

Pioneer House, Pioneer Business Park

North Road

Ellesmere Port

Cheshire CH65 1AD

United Kingdom

Tel: +44 151 550 4 550

Fax: +44 151 550 4 551

cs@biohithealthcare.co.uk

  • Twitter Social Icon